课题基金 / 基金详情

GH16-002, Botswana: Impact Evaluation of Combination HIV Prevention Interventions

GH16-002, Botswana: Impact Evaluation of Combination HIV Prevention Interventions
GH16-002,博茨瓦纳:艾滋病毒预防组合干预措施的影响评估
批准号:
9165897
负责人:
MYRON E ESSEX
金额:
$616.95万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-02-01 至 2021-01-31

项目摘要

项目成果

MYRON E ESSEX的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(由申请人提供) 事实证明,若干新的艾滋病毒预防干预措施在减少艾滋病毒传播方面非常有效,并为遏制和可能扭转撒哈拉以南非洲的流行病带来了希望。模拟研究表明,投资于快速、协调地扩大基于证据的艾滋病毒预防干预措施的组合,包括艾滋病毒检测和咨询(HTC)、男性包皮环切术(MC)、抗逆转录病毒疗法(ART)和预防母婴传播(PMTCT),可以显著降低人口水平的艾滋病毒发病率,而且可能具有成本效益。如果国家和国际机构要证明对综合预防战略的进一步投资是合理的,就需要有严格的循证结果来支持这些人口层面影响的预测。 这笔资金的主要目标是完成对一揽子综合预防措施对博茨瓦纳人口层面艾滋病毒发病率的影响的持续评估,并估计避免艾滋病毒感染的每项费用。总体研究设计是一项配对的社区随机试验,干预组接受联合预防方案,对照组接受标准护理,加强临床、实验室和数据管理。对每个社区随机选择的大约20%的家庭进行了基线家庭调查,以(1)建立艾滋病毒发病率队列,(2)估计联合预防一揽子计划的基线和年度覆盖率。每年对参加基线家庭调查的个人进行跟踪,以评估两个研究部门对研究服务的接受情况,并描述主要结果。每年对艾滋病毒发病队列进行跟踪,以评估36个月内的累计艾滋病毒发病率,这是人们感兴趣的主要研究结果。 将使用针对四个社区对(4个联合预防社区和4个强化护理社区)100%家庭的研究结束调查来估计和比较各武装之间联合预防一揽子计划的摄入量。此外,实验室研究活动将用于绘制研究期间确定的艾滋病毒感染者的基因类型图,以便为加强护理社区和联合预防社区武器的病毒基因图提供信息。 如果观察到联合预防干预减少艾滋病毒发病率的幅度,以及干预的成本和成本效益,将为如何最有效地分配有限的资源以消除艾滋病毒传播的政策和方案设计提供关键信息。这项研究还将提供有价值的数据,说明扩大生物有效干预措施组合的可行性和可接受性,以达到将产生影响的水平。最后,这项研究的数据将对性网络和风险群体以及在不同环境中实施的最有效办法提供信息,从而能够设计更有针对性的艾滋病毒治疗和预防干预措施。
英文摘要
 DESCRIPTION (provided by applicant) Several new HIV prevention interventions have proven to be highly effective at reducing transmission of HIV and have offered hope for containing and possibly reversing epidemics in sub-Saharan Africa. Modeling studies suggest that investment in rapid, coordinated scale-up of a combination of evidence-based HIV prevention interventions, including HIV testing and counseling (HTC), male circumcision (MC), antiretroviral therapy (ART) and prevention of mother-to-child transmission (PMTCT), can significantly reduce population-level HIV incidence and may be cost-effective. Rigorous evidence-based outcomes to support these projections of population-level impact are needed if national and international bodies are to justify further investment in combination prevention strategies. The primary objective of this funding is to complete an ongoing evaluation of the impact of a combination prevention package on population-level HIV incidence in Botswana and estimate the cost per HIV infection averted. The over-arching study design is a pair-matched Community Randomized Trial with an intervention arm that receives the combination prevention package and a control arm that receives standard of care with clinical, laboratory, and data management strengthening. A baseline household survey of approximately 20% of randomly selected households in each community is implemented to (1) establish an HIV incidence cohort and (2) estimate baseline and annual coverage of the combination prevention package. Individuals who enroll in the baseline household survey are followed annually to assess uptake of study services in both study arms and describe major outcomes. The HIV incidence cohort is followed annually to assess cumulative HIV incidence over 36 months, which is the primary study outcome of interest. An end-of-study survey targeting 100% of households in four community pairs (4 combination prevention communities and 4 enhanced care communities) will be used to estimate and compare combination prevention package uptake between arms. Additionally, laboratory research activities will be used to map genotypes from HIV-infected individuals identified during the study to inform viral genotype maps of enhanced care community and combination prevention community arms. Data regarding the magnitude of reduction in HIV incidence with the combination prevention intervention, if a reduction is observed, and the cost and cost-effectiveness of the intervention will provide key information for policy and program design about how to most effectively allocate limited resources to eliminate HIV transmission. The study will also provide valuable data about the feasibility and acceptability of scaling up a combination of biologically efficacious interventions to a level that will have impact. Finally, data from this study will be informative o sexual networks and risk groups and the most effective approaches to implementation in different settings, allowing for the design of more targeted treatment and prevention interventions for HIV.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GH16-002, Botswana: Impact Evaluation of Combination HIV Prevention Interventions
  • 批准号:
    9215524
  • 项目类别:
  • 资助金额:
    $24.61万
  • 财政年份:
    2016
  • 负责人:
    MYRON E ESSEX
  • 依托单位:
Fogarty HIV Research Training Program for Low and Middle-Income Countries
  • 批准号:
    8516232
  • 项目类别:
  • 资助金额:
    $27.24万
  • 财政年份:
    2013
  • 负责人:
    MYRON E ESSEX
  • 依托单位:
Fogarty HIV Research Training Program for Low and Middle-Income Countries
  • 批准号:
    8707593
  • 项目类别:
  • 资助金额:
    $27.24万
  • 财政年份:
    2013
  • 负责人:
    MYRON E ESSEX
  • 依托单位:
Fogarty HIV Research Training Program for Low and Middle-Income Countries
  • 批准号:
    9023615
  • 项目类别:
  • 资助金额:
    $27.24万
  • 财政年份:
    2013
  • 负责人:
    MYRON E ESSEX
  • 依托单位:
国内基金
海外基金
锌粉(002)晶面定向调控及其负极性能强化机理研究
  • 批准号:
    2025JJ70625
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    曹鹏辉
  • 依托单位:
新型核素偶联药载体JBN002-DOTA的开发及其在肿瘤诊疗中的应用
  • 批准号:
    82373174
  • 项目类别:
    面上项目
  • 资助金额:
    60万元
  • 批准年份:
    2023
  • 负责人:
    杨杰
  • 依托单位:
tiRNA-Val-CAC-002介导ITGB3/PI3K/Akt调控FB自噬促进OSF发生机制研究
  • 批准号:
    2023JJ30946
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2023
  • 负责人:
    吴颖芳
  • 依托单位:
双胍新衍生物SMK-002阻断PKM2入核下调脂质合成抑制EMT阻止膀胱癌转移的作用和机制研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    55万元
  • 批准年份:
    2021
  • 负责人:
    杨小平
  • 依托单位: